---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-004321"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T15:59:07.263547+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports preliminary 2023 KIMMTRAK revenue of $235M, announces $300M convertible notes offering

## Summary
- Q4 2023 KIMMTRAK net sales ~$66M; full-year 2023 net sales ~$235M.
- Cash and equivalents at Dec 31, 2023 ~$443M.
- Proposed $300M convertible senior notes due 2030; initial purchasers option for additional $45M.
- Net proceeds to accelerate clinical pipeline, expand commercial, and repay Pharmakon loans.
- Pipeline: tebentafusp Phase 2/3 cutaneous melanoma topline data expected Q4 2024; IMC-F106C Phase 3 first-line melanoma trial first patient randomization Q1 2024.

## SEC filing metadata
- accession: 0001140361-24-004321
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/0001140361-24-004321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/ef20020073_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-004321
- JSON: https://secwatch.observer/filing/0001140361-24-004321.json
- Plain text: https://secwatch.observer/filing/0001140361-24-004321.txt

## Key facts
- Earnings Releases
  Immunocore Holdings plc reported the fourth quarter of 2023 and the full year 2023 results: revenue approximately $66 million.
  - Period: the fourth quarter of 2023 and the full year 2023
  - Revenue: approximately $66 million
  - Result: preliminary results
  source text: Immunocore Holdings plc (the “Company”) expects to report preliminary unaudited net product revenue (“net sales”) arising from the sales of KIMMTRAK (tebentafusp) of approximately $66 million for the fourth quarter of 2023 and approximately $235 million for the full year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/0001140361-24-004321-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.